In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eliza Slawther

Senior Writer

London, UK

Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.

Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.

Latest From Eliza Slawther

Medtech Industry Weighs In On EMA’s AI Regulation Proposals

Alignment with other relevant regulations, including medtech, should be a main priority for the European Medicines Agency when developing guidance on the use of artificial intelligence, according to MedTech Europe’s director for international affairs.

Europe EU

ACCESS Consortium Expands Focus To ATMPs And ‘Urgently Needed’ Medicines

A work-sharing group made up of regulators in Australia, Canada, Singapore, Switzerland and the UK has been expanded to include advanced therapy medicinal products, which could lead to greater harmonization in the regulatory approaches taken by different agencies.

BioPharmaceutical Gene Therapy

Pharma Industry Weighs In On EMA’s AI Regulation Proposals

Consistency and coherence with other relevant regulations should be a main priority for the European Medicines Agency when developing guidance on the use of artificial intelligence in the drug lifecycle, pharmaceutical industry representatives have said.

BioPharmaceutical Medical Device

AI Complexity Not A ‘Free Pass’ To Dodge Regulatory Standards, EMA Warns

Companies that use AI technologies will be responsible for demonstrating that regulatory standards are met and that the data they provide “has not been synthetically generated or completely made up,” an EU workshop heard this week.

BioPharmaceutical Artificial Intelligence

Regulators Need New Skills & Smarter Guidance To Govern AI, Says EMA Chief

A two-day workshop saw EU policymakers and regulators meet with dozens of representatives from the pharmaceutical, health and medtech industries to discuss the future of regulating AI in medicine and its uses in the medicinal product lifecycle.

Europe EU

UK’s Competition Body Says Pharma Firms Can Work Together On Access To Combination Therapies

The UK’s Competition and Markets Authority will not prioritize the investigation of pharmaceutical companies that enter commercial negotiations with the aim of making combination therapies cost effective, a move that the ABPI says is an “international first”.

BioPharmaceutical Pricing Strategies
See All